Advances and perspectives for antimicrobial peptide and combinatory therapies.
antibiotic-therapy combination
antimicrobial resistance
infection medication
infectious diseases
synergic effect
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
09
2022
accepted:
28
11
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
30
12
2022
Statut:
epublish
Résumé
Antimicrobial peptides (AMPs) have shown cell membrane-directed mechanisms of action. This specificity can be effective against infectious agents that have acquired resistance to conventional drugs. The AMPs' membrane-specificity and their great potential to combat resistant microbes has brought hope to the medical/therapeutic scene. The high death rate worldwide due to antimicrobial resistance (AMR) has pushed forward the search for new molecules and product developments, mainly antibiotics. In the current scenario, other strategies including the association of two or more drugs have contributed to the treatment of difficult-to-treat infectious diseases, above all, those caused by bacteria. In this context, the synergistic action of AMPs associated with current antibiotic therapy can bring important results for the production of new and effective drugs to overcome AMR. This review presents the advances obtained in the last 5 years in medical/antibiotic therapy, with the use of products based on AMPs, as well as perspectives on the potentialized effects of current drugs combined with AMPs for the treatment of bacterial infectious diseases.
Identifiants
pubmed: 36578509
doi: 10.3389/fbioe.2022.1051456
pii: 1051456
pmc: PMC9791095
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1051456Informations de copyright
Copyright © 2022 C, G. R, L. F, M.C.G, N.B, S.C and O. L.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with the author CS.
Références
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33649202
J Exp Bot. 2020 Jul 6;71(14):4258-4270
pubmed: 32227083
Pharmaceuticals (Basel). 2022 Feb 21;15(2):
pubmed: 35215373
RSC Adv. 2019 Mar 5;9(13):7239-7245
pubmed: 35519960
Nat Rev Microbiol. 2022 May;20(5):257-269
pubmed: 34737424
Front Microbiol. 2022 Jul 15;13:953720
pubmed: 35910608
Front Med Technol. 2020 Dec 21;2:615494
pubmed: 35047895
Biochem Pharmacol. 2017 Apr 15;130:34-50
pubmed: 28131846
Oncogene. 2020 Jun;39(25):4869-4883
pubmed: 32444694
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31332075
Pharmaceuticals (Basel). 2021 May 17;14(5):
pubmed: 34067510
Perspect Public Health. 2018 Mar;138(2):87-88
pubmed: 29465015
EBioMedicine. 2022 Apr;78:103979
pubmed: 35367773
J Antibiot (Tokyo). 2021 Sep;74(9):547-558
pubmed: 34244614
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28947471
Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1739-1748
pubmed: 28470337
J Control Release. 2019 Jan 10;293:73-83
pubmed: 30465823
PLoS Pathog. 2018 Jun 21;14(6):e1007084
pubmed: 29928049
Annu Rev Biochem. 2018 Jun 20;87:451-478
pubmed: 29570352
Molecules. 2021 Sep 16;26(18):
pubmed: 34577082
Expert Opin Drug Discov. 2021 Jun;16(6):601-604
pubmed: 33626997
JAMA. 2020 Mar 03;323(9):844-853
pubmed: 32125404
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Saudi J Biol Sci. 2017 Jul;24(5):1023-1029
pubmed: 28663698
Cell Metab. 2019 Aug 6;30(2):251-259
pubmed: 31279676
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29914941
Eur J Med Chem. 2017 Aug 18;136:428-441
pubmed: 28525841
Front Microbiol. 2021 Aug 12;12:710199
pubmed: 34475862
ACS Infect Dis. 2021 Mar 12;7(3):672-680
pubmed: 33650856
Antibiotics (Basel). 2022 Mar 19;11(3):
pubmed: 35326876
Int J Pharm. 2017 Jun 30;526(1-2):244-253
pubmed: 28461263
J Infect Public Health. 2021 Dec;14(12):1750-1766
pubmed: 34756812
Elife. 2019 Feb 26;8:
pubmed: 30803481
Curr Opin Chem Biol. 2017 Jun;38:87-96
pubmed: 28399505
Int J Nanomedicine. 2019 Dec 10;14:9777-9792
pubmed: 31849468
Protein Expr Purif. 2021 Dec;188:105949
pubmed: 34324967
J Biol Chem. 2019 Oct 4;294(40):14615-14633
pubmed: 31383740
Clin Pharmacol Ther. 2019 Jun;105(6):1395-1406
pubmed: 30912119
Saudi J Biol Sci. 2017 May;24(4):808-812
pubmed: 28490950
FEBS Lett. 2011 Apr 6;585(7):995-1000
pubmed: 21402074
Front Med Technol. 2020 Dec 11;2:610997
pubmed: 35047892
Int J Biol Macromol. 2022 Apr 15;204:457-465
pubmed: 35151708
Front Microbiol. 2019 Nov 25;10:2719
pubmed: 31824473
Oncotarget. 2017 May 23;8(34):55958-55966
pubmed: 28915566
Sci Rep. 2018 Mar 21;8(1):4964
pubmed: 29563526
Infect Drug Resist. 2019 Jul 11;12:2031-2038
pubmed: 31372011
Infect Drug Resist. 2018 Oct 10;11:1645-1658
pubmed: 30349322
ACS Infect Dis. 2021 Aug 13;7(8):2152-2163
pubmed: 34227804
Med Res Rev. 2022 Jul;42(4):1377-1422
pubmed: 34984699
Medchemcomm. 2017 Jan 26;8(3):516-533
pubmed: 30108769
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28483966
Future Microbiol. 2018 Feb;13:151-163
pubmed: 29308671
Antibiotics (Basel). 2019 May 09;8(2):
pubmed: 31075940
Sci Rep. 2017 Oct 13;7(1):13153
pubmed: 29030606
Fundam Clin Pharmacol. 2020 Feb;34(1):102-108
pubmed: 31313350
Curr Opin Microbiol. 2019 Oct;51:72-80
pubmed: 31733401
Front Microbiol. 2019 Aug 09;10:1703
pubmed: 31447797
Biophys Chem. 2016 Mar;210:35-44
pubmed: 26099623
BMC Microbiol. 2019 Mar 8;19(1):54
pubmed: 30849936
Molecules. 2020 Jul 17;25(14):
pubmed: 32708842
Mil Med Res. 2021 Sep 9;8(1):48
pubmed: 34496967
Microbiol Spectr. 2022 Aug 31;10(4):e0097322
pubmed: 35862981
Front Chem. 2018 Jun 05;6:204
pubmed: 29922648
Antibiotics (Basel). 2021 Apr 07;10(4):
pubmed: 33917043
Antibiotics (Basel). 2022 Jan 30;11(2):
pubmed: 35203785
Front Microbiol. 2017 Dec 07;8:2409
pubmed: 29375486
Front Pharmacol. 2021 Nov 22;12:790817
pubmed: 34880766
ACS Infect Dis. 2020 Jun 12;6(6):1405-1412
pubmed: 31566948
Microb Drug Resist. 2018 Jul/Aug;24(6):747-767
pubmed: 29957118
mSphere. 2017 Dec 6;2(6):
pubmed: 29242830
Theranostics. 2021 Mar 4;11(10):4910-4928
pubmed: 33754035
J Infect Dis. 2010 Nov 15;202(10):1585-92
pubmed: 20942647
R Soc Open Sci. 2022 Jan 26;9(1):211583
pubmed: 35116161
Nat Rev Microbiol. 2022 Aug;20(8):478-490
pubmed: 35241807
J Phys Chem Lett. 2020 Nov 5;11(21):9501-9506
pubmed: 33108730
Adv Healthc Mater. 2018 Oct;7(20):e1800354
pubmed: 29923332
Pharmaceuticals (Basel). 2022 Jan 28;15(2):
pubmed: 35215278
Future Microbiol. 2021 Mar;16:221-227
pubmed: 33646013
Molecules. 2020 Nov 30;25(23):
pubmed: 33266085
Langmuir. 2020 Jul 7;36(26):7190-7199
pubmed: 32529830
Mol Ecol. 2017 Oct;26(19):5334-5343
pubmed: 28762573
Front Cell Infect Microbiol. 2020 Jul 07;10:326
pubmed: 32733816
J Infect Dis. 2004 Oct 15;190(8):1476-80
pubmed: 15378441
Microb Pathog. 2021 Jan;150:104700
pubmed: 33346078
Front Microbiol. 2019 Dec 12;10:2866
pubmed: 31921046
Molecules. 2018 Feb 01;23(2):
pubmed: 29389911
Front Chem. 2018 Aug 14;6:309
pubmed: 30155456
Front Microbiol. 2021 Oct 18;12:747760
pubmed: 34733262
Infect Drug Resist. 2020 Dec 29;13:4713-4738
pubmed: 33402841
J Pept Sci. 2017 Apr;23(4):329-333
pubmed: 28176481
Int J Mol Sci. 2021 Jul 12;22(14):
pubmed: 34299085
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764495
Front Med Technol. 2021 Mar 12;3:640981
pubmed: 35047912
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9869-E9878
pubmed: 30275324
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262767
J Antibiot (Tokyo). 2022 Mar;75(3):181-184
pubmed: 35091666
Front Cell Infect Microbiol. 2021 Jun 14;11:668632
pubmed: 34195099
Front Immunol. 2020 May 22;11:983
pubmed: 32528474
Biochim Biophys Acta Biomembr. 2017 May;1859(5):722-733
pubmed: 28161291
Microb Drug Resist. 2019 Mar;25(2):193-202
pubmed: 30281385
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061285
Drug Des Devel Ther. 2017 Mar 22;11:939-946
pubmed: 28356719
Mol Med Rep. 2019 Apr;19(4):3337-3344
pubmed: 30816474
Front Pharmacol. 2022 Feb 23;13:839808
pubmed: 35281905
Infect Drug Resist. 2019 Dec 20;12:3903-3910
pubmed: 31908502
Trans Am Acad Ophthalmol Otolaryngol. 1951 May-Jun;55:524-35
pubmed: 14855535
Commun Biol. 2021 Jan 4;4(1):31
pubmed: 33398076
Microb Pathog. 2021 Sep;158:105056
pubmed: 34153416
Antimicrob Agents Chemother. 2020 Jan 27;64(2):
pubmed: 31740560
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28533232